Kurma, K.; Zeybek Kuyucu, A.; Roth, G.S.; Sturm, N.; Mercey-Ressejac, M.; Abbadessa, G.; Yu, Y.; Lerat, H.; Marche, P.N.; Decaens, T.;
et al. Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. Int. J. Mol. Sci. 2022, 23, 16206.
https://doi.org/10.3390/ijms232416206
AMA Style
Kurma K, Zeybek Kuyucu A, Roth GS, Sturm N, Mercey-Ressejac M, Abbadessa G, Yu Y, Lerat H, Marche PN, Decaens T,
et al. Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. International Journal of Molecular Sciences. 2022; 23(24):16206.
https://doi.org/10.3390/ijms232416206
Chicago/Turabian Style
Kurma, Keerthi, Ayca Zeybek Kuyucu, Gaël S. Roth, Nathalie Sturm, Marion Mercey-Ressejac, Giovanni Abbadessa, Yi Yu, Herve Lerat, Patrice N. Marche, Thomas Decaens,
and et al. 2022. "Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model" International Journal of Molecular Sciences 23, no. 24: 16206.
https://doi.org/10.3390/ijms232416206
APA Style
Kurma, K., Zeybek Kuyucu, A., Roth, G. S., Sturm, N., Mercey-Ressejac, M., Abbadessa, G., Yu, Y., Lerat, H., Marche, P. N., Decaens, T., & Macek Jilkova, Z.
(2022). Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. International Journal of Molecular Sciences, 23(24), 16206.
https://doi.org/10.3390/ijms232416206